Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Loqular vs Avigan in Healthy Male Subjects
NCT04407000Phase 1Completed
- Sponsor
- World Medicine
- Start
- Jun 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of favipiravir in influenza (2 arms), sponsored by World Medicine. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 12 weeks and Maximum Plasma Concentration at 13 weeks. Started Jun 2020; status: completed.
02
Drugs
favipiravir
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04407000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04407000.